| PFS | OS | ||
---|---|---|---|---|
 | AHR (95% CI) | P-value | AHR (95% CI) | P-value |
NER | ||||
 <Median | 0.62 (0.39–0.98) | 0.04 | 0.32 (0.14–0.72) | 0.006 |
 >Median | Ref |  | Ref |  |
Age | ||||
 Age > 60 | 0.82 (0.51–1.31) | 0.41 | 1.06 (0.51–2.19) | 0.88 |
 Age < 60 | Ref |  | Ref |  |
Race | ||||
 Non-White | 0.65 (0.30–1.41) | 0.28 | 0.42 (0.10–1.83) | 0.25 |
 White | Ref |  | Ref |  |
Sex | ||||
 Male | 1.02 (0.61–1.69) | 0.95 | 1.32 (0.57–3.06) | 0.52 |
 Female | Ref |  | Ref |  |
IMDC | ||||
 Poor | 2.36 (1.08–5.14) | 0.03 | 3.81 (0.95–15.33) | 0.06 |
 Intermediate | 1.31 (0.69–2.46) | 0.41 | 1.95 (0.57–6.71) | 0.29 |
 Favorable | Ref |  | Ref |  |
Prior systemic therapy | ||||
 Yes | 1.78 (1.09–2.90) | 0.02 | 0.69 (0.29–1.62) | 0.39 |
 No | Ref |  | Ref |  |